David Qualls1, Andrew Sullivan2, Shuli Li3, Andrew M Brunner4, Kerry Collier5, Ephraim Hochberg6, Philippe Armand7, Tracy T Batchelor8, Yi-Bin Chen5, Zachariah DeFilipp9. 1. Department of Medicine, Massachusetts General Hospital, Boston, MA. 2. Memorial University School of Medicine, St John's, Newfoundland, Canada. 3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA. 4. Center for Leukemia, Massachusetts General Hospital, Boston, MA. 5. Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA. 6. Center for Lymphoma, Massachusetts General Hospital, Boston, MA. 7. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA. 8. Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA. 9. Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA. Electronic address: zdefilipp@mgh.harvard.edu.
Abstract
INTRODUCTION: Synchronous involvement of the central nervous system (CNS) at the diagnosis of systemic non-Hodgkin lymphoma (NHL) is associated with an increased risk for relapse despite complete remission to initial therapy. High-dose chemotherapy with a CNS-directed conditioning regimen followed by autologous stem cell transplantation (ASCT) holds promise as a consolidative approach. PATIENTS AND METHODS: We conducted a retrospective analysis of all patients with systemic B-cell NHL and synchronous CNS involvement who received upfront consolidation with high-dose chemotherapy with thiotepa, busulfan, cyclophosphamide, and ASCT while in first complete remission between July 2008 and June 2016 at 2 partner academic institutions. RESULTS: Twenty patients were identified through the transplant database. The median age at diagnosis was 53 years (range, 37-65 years). The majority had diffuse large B-cell lymphoma histology (n = 17; 85%). The sites of CNS involvement were parenchymal (n = 12; 60%) and leptomeningeal disease (n = 9; 45%). All patients received systemic and CNS-directed therapy prior to transplant, with the most common approaches being R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) (n = 13; 65%) and high-dose intravenous methotrexate (n = 16; 80%), respectively. With a median follow up of 4.4 years after ASCT (range, 2 months-8.5 years), the Kaplan-Meier estimates of 4-year progression-free and overall survival were 77% (95% confidence interval, 48%-91%) and 82% (95% confidence interval, 54%-94%), respectively. CONCLUSION: CNS-directed high-dose chemotherapy and ASCT provides durable remission for patients with synchronous aggressive lymphoma and should be strongly considered as consolidative therapy for eligible patients with systemic NHL with CNS involvement in first complete remission.
INTRODUCTION: Synchronous involvement of the central nervous system (CNS) at the diagnosis of systemic non-Hodgkin lymphoma (NHL) is associated with an increased risk for relapse despite complete remission to initial therapy. High-dose chemotherapy with a CNS-directed conditioning regimen followed by autologous stem cell transplantation (ASCT) holds promise as a consolidative approach. PATIENTS AND METHODS: We conducted a retrospective analysis of all patients with systemic B-cell NHL and synchronous CNS involvement who received upfront consolidation with high-dose chemotherapy with thiotepa, busulfan, cyclophosphamide, and ASCT while in first complete remission between July 2008 and June 2016 at 2 partner academic institutions. RESULTS: Twenty patients were identified through the transplant database. The median age at diagnosis was 53 years (range, 37-65 years). The majority had diffuse large B-cell lymphoma histology (n = 17; 85%). The sites of CNS involvement were parenchymal (n = 12; 60%) and leptomeningeal disease (n = 9; 45%). All patients received systemic and CNS-directed therapy prior to transplant, with the most common approaches being R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) (n = 13; 65%) and high-dose intravenous methotrexate (n = 16; 80%), respectively. With a median follow up of 4.4 years after ASCT (range, 2 months-8.5 years), the Kaplan-Meier estimates of 4-year progression-free and overall survival were 77% (95% confidence interval, 48%-91%) and 82% (95% confidence interval, 54%-94%), respectively. CONCLUSION: CNS-directed high-dose chemotherapy and ASCT provides durable remission for patients with synchronous aggressive lymphoma and should be strongly considered as consolidative therapy for eligible patients with systemic NHL with CNS involvement in first complete remission.
Authors: Michael Scordo; Sejal M Morjaria; Eric R Littmann; Ankush Bhatia; Helen H Chung; Molly Maloy; Lisa M DeAngelis; Sergio A Giralt; Ying Taur; Craig S Sauter Journal: Biol Blood Marrow Transplant Date: 2018-04-18 Impact factor: 5.742
Authors: Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter Journal: JAMA Oncol Date: 2021-07-01 Impact factor: 31.777
Authors: Serkan Akin; Chitra Hosing; Issa Khouri; Sairah Ahmed; Amin Alousi; Nathan Fowler; Jacinth Joseph; Jonathan Truxillo; Jeremy L Ramdial; Farzaneh Maadani; Gabriela Rondon; May Daher; Jin S Im; Raphael Steiner; Jason Westin; Swaminathan P Iyer; Bouthaina Dabaja; Paolo Anderlini; Uday R Popat; Muzaffar H Qazilbash; Christopher R Flowers; Elizabeth Shpall; Richard E Champlin; Yago Nieto; Samer A Srour Journal: Blood Adv Date: 2022-04-12
Authors: Patricia A Young; Daria Gaut; Davis K Kimaiyo; Jonathan Grotts; Tahmineh Romero; John Chute; Gary Schiller; Sven de Vos; Herbert A Eradat; John Timmerman Journal: Clin Lymphoma Myeloma Leuk Date: 2020-02-20